Inhibrx Biosciences, Inc. (NASDAQ:INBX) Receives Consensus Rating of "Hold" from Brokerages

Key Points

• Analysts have assigned a consensus rating of Hold on Inhibrx from five covering brokers (1 sell, 3 hold, 1 buy), with an average 12‑month price target of $150.
• Institutional ownership is high at 82.46%, with notable moves including Invesco increasing its stake by 539.6% to 112,396 shares (about $8.88M) in the latest quarter.
• The stock trades around $75.27 with a market cap of $1.10B (one‑year range $10.81–$94.57), and the company reported ($2.11) EPS for the quarter, missing estimates by $0.03.

Inhibrx Biosciences, Inc. (NASDAQ:INBX - Get Free Report) has been assigned a consensus rating of "Hold" from the five analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $150.00.

INBX has been the subject of several analyst reports. Zacks Research upgraded Inhibrx Biosciences to a "hold" rating in a research note on Thursday. Stifel Nicolaus initiated coverage on Inhibrx Biosciences in a research note on Wednesday. They issued a "buy" rating and a $150.00 price objective for the company. Wall Street Zen lowered Inhibrx Biosciences from a "hold" rating to a "sell" rating in a research note on Saturday. Finally, Weiss Ratings restated a "sell (d)" rating on shares of Inhibrx Biosciences in a research note on Thursday, January 22nd.

Institutional Investors Weigh In On Inhibrx Biosciences

A number of institutional investors have recently bought and sold shares of the business. Corient Private Wealth LLC purchased a new stake in Inhibrx Biosciences in the 4th quarter worth $1,615,000. Invesco Ltd. increased its stake in Inhibrx Biosciences by 539.6% in the 4th quarter. Invesco Ltd. now owns 112,396 shares of the company's stock worth $8,879,000 after buying an additional 94,822 shares in the last quarter. XTX Topco Ltd purchased a new stake in Inhibrx Biosciences in the 4th quarter worth $713,000. Virtus Investment Advisers LLC purchased a new stake in Inhibrx Biosciences in the 4th quarter worth $264,000. Finally, SummitTX Capital L.P. increased its stake in Inhibrx Biosciences by 53.1% in the 4th quarter. SummitTX Capital L.P. now owns 82,885 shares of the company's stock worth $6,548,000 after buying an additional 28,742 shares in the last quarter. Hedge funds and other institutional investors own 82.46% of the company's stock.

Inhibrx Biosciences Stock Down 0.6%

Inhibrx Biosciences stock opened at $75.27 on Friday. The stock has a market cap of $1.10 billion, a PE ratio of -8.33 and a beta of 1.82. The company has a debt-to-equity ratio of 12.58, a quick ratio of 3.93 and a current ratio of 3.93. Inhibrx Biosciences has a one year low of $10.81 and a one year high of $94.57. The stock has a fifty day moving average of $72.94 and a 200 day moving average of $69.46.

Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) last posted its quarterly earnings data on Thursday, March 19th. The company reported ($2.11) EPS for the quarter, missing analysts' consensus estimates of ($2.08) by ($0.03). As a group, sell-side analysts predict that Inhibrx Biosciences will post 104.88 EPS for the current year.

About Inhibrx Biosciences

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company's proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company's lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.